Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Intellia Thera CS (NQ: NTLA)
26.78 USD  -4.73 (-15.01%)
Official Closing Price  /  Updated: 7:42 PM EDT, Sep 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,673,600
Open 31.51
Bid (Size) 27.20 (2)
Ask (Size) 27.50 (10)
Prev. Close 31.51
Today's Range 26.74 - 31.51
52wk Range 16.33 - 35.99
Shares Outstanding 43,089,810
Dividend Yield N/A
Performance
YTD
+24.50%
+24.50%
1 Month
-6.27%
-6.27%
3 Month
-5.54%
-5.54%
6 Month
+11.35%
+11.35%
1 Year
+8.42%
+8.42%
Top News
More News
Intellia Therapeutics Scores Relative Strength Rating Upgrade
Intellia Therapeutics sees its Relative Strength Rating hit the elite 90-plus level. Read More
from Investor's Business Daily
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Re
CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”)... Read More
from GlobeNewswire News Releases
More News
Read More
This Gene-Editing Biotech Toppled On A Deal In Diabetes
from Investor's Business Daily
Stocks Flashing Renewed Technical Strength: Intellia Therapeutics
from Investor's Business Daily
Intellia Therapeutics Earns RS Rating Upgrade
from Investor's Business Daily
Intellia Therapeutics to Present at September Healthcare Investor Conferences
from GlobeNewswire News Releases
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
from GlobeNewswire News Releases
Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents
from GlobeNewswire News Releases
F-star Appoints Nessan Bermingham as Chairman of its Board of Directors
from Business Wire News Releases
Detailed Research: Economic Perspectives on IQVIA, Intellia Therapeutics, Deluxe, Superior Industries International, The Navigators Group, and CAI International — What Drives Growth in Today's Competi
from GlobeNewswire News Releases
Intellia Therapeutics Announces Second Quarter 2018 Financial Results
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X